Fakeeh Care inks MoU with Fosun Pharma to develop cell, gene therapies

Dr. Soliman Abdel Kader Fakeeh Hospital Co. (Fakeeh Care) and its subsidiaries, Fakeeh Care Group and Fakeeh Care, signed a strategic memorandum of understanding (MoU) with global innovator Shanghai Fosun Pharmaceutical Co. Ltd. to bring advanced cell- and gene-therapy solutions—most notably CAR-T—as well as AI-powered digital pathology and remote diagnostics to the Kingdom.

Aligned with Saudi Vision 2030, the partnership seeks to accelerate local development and delivery of cutting-edge treatments, enhance diagnostic accuracy, and establish Saudi Arabia as a regional hub for healthcare innovation, the company said in a statement to Tadawul.

Advanced cell and gene therapy solutions, as well as AI-powered digital pathology and remote diagnostic services, will be introduced to the Kingdom of Saudi Arabia, the statement added.

The company explained that the MoU was signed on April 27, 2025, and is valid for one year.